📊 LSTA Key Takeaways
Is Lisata Therapeutics, Inc.. (LSTA) a Good Investment?
Lisata Therapeutics is a pre-revenue pharmaceutical company with only $170K in annual revenue (down 83% YoY), burning $15.9M in operating cash flow annually against just $16M in total cash reserves. At the current burn rate, the company has approximately 12 months of cash runway with no clear path to profitability or revenue generation.
Fundamentals show immaterial and declining revenue, extreme negative margins, and heavy operating cash burn. While liquidity is solid near term with no debt and ~12 months of cash, the business lacks visible path to scale or profitability. Without clear, recurring non-dilutive revenue or sharply lower operating losses, dilution and going‑concern risks dominate.
Why Buy Lisata Therapeutics, Inc.. Stock? LSTA Key Strengths
- Strong liquidity position with 5.76x current ratio and 5.07x quick ratio
- Zero long-term debt with conservative capital structure
- Stockholders' equity of $14.9M provides cushion against insolvency
- Strong liquidity (current ratio 5.76x) with $15.96M cash
- Debt-free balance sheet and low liabilities
- Minimal capex needs and modest EPS YoY improvement
LSTA Stock Risks: Lisata Therapeutics, Inc.. Investment Risks
- Minimal revenue ($170K) with 83% YoY decline indicates failed commercialization or pipeline delays
- Annual operating cash burn of $15.9M against $16M cash reserves (approximately 12-month runway)
- Deeply negative profitability metrics across all measures (operating margin -10,711%, net margin -9,757%)
- Nine Form 4 insider filings in 90 days suggest elevated uncertainty or potential capital structure concerns
- High cash burn (~$16M OCF) implying ~1-year runway
- Severely negative margins and -83% YoY revenue decline
- Elevated dilution/going-concern risk absent funding or cost reduction
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway calculations
- Revenue trajectory and new product commercialization milestones
- Clinical trial progression and regulatory approvals for pipeline candidates
- Quarterly operating cash burn and cash runway
- Recurring non-dilutive revenue growth and operating expense trend
Lisata Therapeutics, Inc.. (LSTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.76x current ratio provides a solid financial cushion.
LSTA Profit Margin, ROE & Profitability Analysis
LSTA vs Healthcare Sector: How Lisata Therapeutics, Inc.. Compares
How Lisata Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lisata Therapeutics, Inc.. Stock Overvalued? LSTA Valuation Analysis 2026
Based on fundamental analysis, Lisata Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lisata Therapeutics, Inc.. Balance Sheet: LSTA Debt, Cash & Liquidity
LSTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lisata Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.58 indicates the company is currently unprofitable.
LSTA Revenue Growth, EPS Growth & YoY Performance
LSTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.2M | $-0.49 |
| Q2 2025 | N/A | -$4.7M | $-0.54 |
| Q1 2025 | N/A | -$4.7M | $-0.55 |
| Q3 2024 | N/A | -$4.9M | $-0.59 |
| Q2 2024 | N/A | -$4.0M | $-0.50 |
| Q1 2024 | N/A | -$5.4M | $-0.65 |
| Q3 2023 | N/A | -$5.3M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lisata Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
LSTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lisata Therapeutics, Inc.. (CIK: 0000320017)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LSTA
What is the AI rating for LSTA?
Lisata Therapeutics, Inc.. (LSTA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LSTA's key strengths?
Claude: Strong liquidity position with 5.76x current ratio and 5.07x quick ratio. Zero long-term debt with conservative capital structure. ChatGPT: Strong liquidity (current ratio 5.76x) with $15.96M cash. Debt-free balance sheet and low liabilities.
What are the risks of investing in LSTA?
Claude: Minimal revenue ($170K) with 83% YoY decline indicates failed commercialization or pipeline delays. Annual operating cash burn of $15.9M against $16M cash reserves (approximately 12-month runway). ChatGPT: High cash burn (~$16M OCF) implying ~1-year runway. Severely negative margins and -83% YoY revenue decline.
What is LSTA's revenue and growth?
Lisata Therapeutics, Inc.. reported revenue of $170.0K.
Does LSTA pay dividends?
Lisata Therapeutics, Inc.. does not currently pay dividends.
Where can I find LSTA SEC filings?
Official SEC filings for Lisata Therapeutics, Inc.. (CIK: 0000320017) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LSTA's EPS?
Lisata Therapeutics, Inc.. has a diluted EPS of $-1.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LSTA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lisata Therapeutics, Inc.. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LSTA stock overvalued or undervalued?
Valuation metrics for LSTA: ROE of -111.7% (sector avg: 15%), net margin of -9,756.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LSTA stock in 2026?
Our dual AI analysis gives Lisata Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LSTA's free cash flow?
Lisata Therapeutics, Inc..'s operating cash flow is $-15.9M, with capital expenditures of $28.0K. FCF margin is -9,398.2%.
How does LSTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,756.5% (avg: 12%), ROE -111.7% (avg: 15%), current ratio 5.76 (avg: 2).